Test duvelisib plus chidamide for newly diagnosed PTCL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial studies whether the combination of duvelisib and chidamide can treat newly diagnosed peripheral T-cell lymphoma (PTCL). Because it is a single-arm study, everyone gets the treatment, and the team monitors response and safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 70 (including 18 and 70).
- You have a new diagnosis of PTCL confirmed by a tissue biopsy, like AITL or other T-helper–type PTCL.
- You have not had any prior whole-body (systemic) lymphoma treatment and you are not currently on anti-cancer treatment.
- Your general health is limited but still workable (ECOG score 3 or lower).
- There is at least one measurable or assessable tumor spot the doctors can track on scans.
- You do not have certain serious exclusions, like lymphoma in the brain/spinal fluid (CNS), uncontrolled infections, major recent heart problems, HIV/hepatitis B or C, or pregnancy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs, Chidamide and Duvalisib, for people with peripheral T-cell lymphoma or NK/T-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this drug combination can help shrink or control the lymphoma.
This trial tests a combination of two drugs, linperlisib and chidamide, for people whose peripheral T-cell lymphoma has come back or not responded to at least one prior treatment. The goal is to see if this combination can shrink or control the lymphoma.
This study tests two oral drugs—duvelisib and venetoclax—to see if together they can help people with a type of lymphoma called peripheral T-cell lymphoma (PTCL) that has not responded to at least two prior treatments.
This trial tests two pills—linperlisib and chidamide—for people with a type of lymphoma called PTCL. The combination might work better together than either alone.
This trial tests whether the drug duvelisib can help keep T-cell lymphoma in remission after initial chemotherapy. It is for people who have finished first-line treatment with a CHOP-like regimen, achieved a complete response, and cannot or choose not to have a stem cell transplant.
This trial is testing a combination of two targeted drugs – chidamide (an HDAC inhibitor) and golidocitinib (a JAK inhibitor) – for people with peripheral T-cell lymphoma that has come back or hasn't responded to prior treatments. The goal is to see if this combination can shrink tumors or stop the cancer from growing.
Hear when a new Newly Diagnosed Peripheral T-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.